Literature DB >> 15488754

Guilty as charged: B-RAF is a human oncogene.

Mathew J Garnett1, Richard Marais.   

Abstract

RAF proteins are components of a conserved signaling pathway that regulates cellular responses to extracellular signals. Despite over 20 years of research into the regulation and function of the RAF proteins, it was only realized recently that the B-RAF isoform is mutated at a high frequency in human cancer. Here we review the rapid progress made in our understanding of B-RAF as an oncogene and of its role in cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15488754     DOI： 10.1016/j.ccr.2004.09.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  253 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

Review 2.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

3.  TRAF6 promoted the metastasis of esophageal squamous cell carcinoma.

Authors:  Qingqi Han; Feng Yao; Chenxi Zhong; Heng Zhao
Journal:  Tumour Biol       Date:  2013-09-13

4.  In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.

Authors:  Zi-jie Wang; Zhi-ning Wan; Xu-dong Chen; Chuan-fang Wu; Guo-long Gao; Rong Liu; Zheng Shi; Jin-ku Bao
Journal:  J Mol Model       Date:  2015-04-02       Impact factor: 1.810

5.  Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases.

Authors:  Kazuya Terasawa; Katsuhiko Yoshimatsu; Shun-Ichiro Iemura; Tohru Natsume; Keiji Tanaka; Yasufumi Minami
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

6.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

7.  Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.

Authors:  Brennan Decker; Heidi G Parker; Deepika Dhawan; Erika M Kwon; Eric Karlins; Brian W Davis; José A Ramos-Vara; Patty L Bonney; Elizabeth A McNiel; Deborah W Knapp; Elaine A Ostrander
Journal:  Mol Cancer Res       Date:  2015-03-12       Impact factor: 5.852

Review 8.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

9.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

10.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.